Welcome to our dedicated page for Taysha Gene Therapies news (Ticker: TSHA), a resource for investors and traders seeking the latest updates and insights on Taysha Gene Therapies stock.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) is a clinical-stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its news flow is heavily centered on TSHA-102, a self-complementary, intrathecally delivered AAV9 investigational gene transfer therapy in clinical evaluation for Rett syndrome.
On this TSHA news page, readers can follow company announcements about clinical progress in the REVEAL Phase 1/2 and pivotal trials, as well as the ASPIRE safety-focused study in younger females with Rett syndrome. Taysha regularly reports on enrollment status, dosing milestones, interim and longer-term safety and efficacy data, and supplemental analyses of functional outcomes and developmental milestones achieved post-TSHA-102.
Investors and followers of TSHA stock will also find regulatory updates, such as the FDA’s Breakthrough Therapy designation for TSHA-102 and alignment on pivotal trial protocols and statistical analysis plans intended to support a future Biologics License Application. Additional news items include financial results, capital-raising activities, amendments to at-the-market equity programs, and inducement grants of stock options under the company’s inducement plan.
Because Rett syndrome is a rare neurodevelopmental disorder with no approved disease-modifying therapies that address its genetic root cause, developments from Taysha’s TSHA-102 program are closely watched by patients, caregivers and market participants. This page aggregates these company-issued updates so that readers can monitor how clinical data, regulatory interactions and corporate actions may shape the trajectory of TSHA-102 and the broader Taysha pipeline over time.
Taysha Gene Therapies (NASDAQ: TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS disorders, has scheduled its Q1 2025 financial results release and corporate update for May 15, 2025, at 8:30 AM ET. The company will host a conference call and webcast accessible via toll-free and international dial-in numbers, with a dedicated conference ID. Investors and interested parties can also access the webcast through Taysha's investor relations website.
Taysha Gene Therapies (TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS disorders, has announced new stock option grants. The Compensation Committee approved options for 822,000 shares to five new employees on April 1, 2025, under the company's 2023 Inducement Plan.
The options were granted at an exercise price of $1.265, matching the closing price on the grant date. These 10-year options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following 36 months, contingent on continued employment.
Taysha Gene Therapies (TSHA), a clinical-stage biotech company specializing in AAV-based gene therapies for CNS diseases, has granted stock options to three new employees. The Compensation Committee approved options to purchase 225,000 shares of common stock on March 3, 2025, under the company's 2023 Inducement Plan.
The options were granted at an exercise price of $1.62 per share, matching the closing price on the grant date. These 10-year options will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following 36 months, contingent on continued employment.
Taysha Gene Therapies (NASDAQ: TSHA) has reported its full-year 2024 financial results and provided updates on its TSHA-102 gene therapy program for Rett syndrome. The company has completed dosing of 10 patients in Part A of both REVEAL trials, with 6 patients receiving high dose (1x1015 total vg) and 4 receiving low dose (5.7x1014 total vg).
Key highlights include no treatment-related serious adverse events or dose-limiting toxicities across all treated patients. The company expects to provide updates on the pivotal trial design and clinical data from both REVEAL trials in H1 2025.
Financial results show R&D expenses increased to $66.0 million in 2024 from $56.8 million in 2023, while G&A expenses decreased slightly to $29.0 million. Net loss for 2024 was $89.3 million ($0.36 per share). The company reported cash and cash equivalents of $139.0 million, expected to support operations into Q4 2026.
Taysha Gene Therapies (TSHA), a clinical-stage biotechnology company specializing in AAV-based gene therapies for CNS disorders, has announced it will release its full-year 2024 financial results and host a corporate update conference call on February 26, 2025. The event will take place at 8:30 AM Eastern Time.
The company has provided both domestic and international dial-in numbers for interested parties to participate in the conference call, which will also be accessible via webcast through the company's investor relations website.
Taysha Gene Therapies (TSHA) has announced the granting of stock options to three new employees as inducement awards. The Compensation Committee approved options to purchase a total of 491,000 shares of common stock under the company's 2023 Inducement Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options were granted at an exercise price of $1.53, matching the closing price on the grant date. These options have a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting in equal monthly installments over the following 36 months. Vesting is contingent upon continued employment with Taysha.
Taysha Gene Therapies (Nasdaq: TSHA) announced that its Compensation Committee has granted a stock option to one new employee on January 2, 2025. The grant includes options to purchase 311,000 shares of common stock at an exercise price of $1.85 per share, matching the closing price on the grant date. The stock option was issued under the company's 2023 Inducement Plan, complying with Nasdaq Listing Rule 5635(c)(4). The option has a 10-year term and follows a four-year vesting schedule: 25% vests after the first year, with the remaining 75% vesting monthly over the following 36 months, contingent on continued employment.
Taysha Gene Therapies (Nasdaq: TSHA) has announced that its Compensation Committee granted a stock option to one new employee on December 2, 2024. The inducement grant, issued under the company's 2023 Inducement Plan and in accordance with Nasdaq Listing Rule 5635(c)(4), consists of an option to purchase 152,000 shares of common stock at an exercise price of $3.08 per share. The option has a 10-year term and will vest over four years, with 25% vesting after the first year and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.
Taysha Gene Therapies (TSHA) reported Q3 2024 financial results and provided updates on its TSHA-102 program. The high dose treatment was well-tolerated with no serious adverse events across both adult and pediatric trials. The FDA approved the use of pivotal product in REVEAL trials and endorsed the commercial manufacturing process. Research and development expenses increased to $14.9 million from $11.8 million year-over-year, while net loss decreased to $25.5 million from $117.1 million. The company has $157.7 million in cash, expected to support operations into Q4 2026. Clinical data from both REVEAL trials' cohorts is expected in H1 2025.
FAQ
What is the current stock price of Taysha Gene Therapies (TSHA)?
What is the market cap of Taysha Gene Therapies (TSHA)?
